Dallas, Texas (PRWEB) May 17, 2014
Diabetes is usually associated with progressive damage to the nervous system, which leads to disorders collectively known as diabetic neuropathy. Diabetic neuropathy is characterized by progressive damage to the neuronal myelin sheath, which slows down nerve conduction velocity. Axonal damage associated with diabetic neuropathy decreases nerve action potential below normal physiological level, which inhibits neuronal signal transmission. About 60 to 70 percent of the diabetic population develops neuropathy, with a considerable number of cases going undiagnosed during the initial years of progression. Disease management should start with the initial diagnosis of diabetes, from educating patients to giving them regular check-ups. Diabetic neuropathy treatment involves bringing blood glucose levels within the normal range to check for further nerve damage and also additional treatment to provide symptomatic relief. Alternative therapies, which help in managing pain, such as biofeedback, meditation, acupuncture or other relaxation techniques can also be used.
Analysts forecast the Global Diabetic Neuropathy market will grow at a CAGR of 8.41 percent over the period 2014-2018.
This report covers the present scenario and the growth prospects of the Global Diabetic Neuropathy market for the period 2014-2018. To calculate the market size, the report considers revenue generated through the sales of various pain management drugs administered to relieve the pain symptoms associated with diabetic neuropathy. The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the Global Diabetic Neuropathy market. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.
Global Diabetic Neuropathy Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Diabetic Neuropathy market landscape and its growth prospects in the coming years.
- Eli Lilly and Co.
- Janssen Pharmaceuticals Inc.
- Pfizer Inc.
Purchase Report @ http://www.sandlerresearch.org/purchase?rname=16971.
Other Prominent Vendors
- Actavis plc
- Cephalon Inc.
- MEDA Pharma GmbH & Co. KG
Key Market Driver
- Increasing Global Diabetic Population.
Key Market Challenge
- High Failure Rate in Clinical Trials.
Key Market Trend
- Increasing R&D Activities.
Key Questions Answered in this Report
- What will the market size be in 2018 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?
List of Exhibits:
Exhibit 1: Market Research Methodology
Exhibit 2: Global Diabetic Neuropathy Market 2013-2018 (US$ billion)
Exhibit 3: Global Diabetic Neuropathy Market by Geographical Segmentation 2013
Exhibit 4: Eli Lilly and Company: Business Segmentation
Exhibit 5: Diabetic Neuropathy Pipeline Snapshot 2013
Exhibit 6: Discontinued Pipeline Molecules on the basis of MOA
Sandlerresearch.org (http://www.sandlerresearch.org/) is an online market research store for research reports on multiple industries. These reports provide market analysis, trends and opportunities and forecast about industries that helps to make a right decision for the business.